sr141716 has been researched along with Brain Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bifulco, M; Catapano, G; Ciaglia, E; D'Alessandro, A; Fiore, D; Gazzerro, P; Laezza, C; Malfitano, AM; Pagano Zottola, AC; Picardi, P; Pisanti, S; Proto, MC; Torelli, G | 1 |
Corbacho, C; de Ceballos, ML; Galve-Roperh, I; Gomez del Pulgar, T; Guzmán, M; Huffman, JW; Ramón y Cajal, S; Rueda, D; Sánchez, C; Velasco, G | 1 |
2 other study(ies) available for sr141716 and Brain Neoplasms
Article | Year |
---|---|
Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; G1 Phase Cell Cycle Checkpoints; Glioma; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Mice; Mice, Nude; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA Interference; RNA, Small Interfering; STAT3 Transcription Factor; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2015 |
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytoma; Benzoxazines; Brain Neoplasms; Camphanes; Cannabinoids; Cell Division; Ceramides; Glioma; Growth Inhibitors; Humans; Mice; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |